Cargando…

Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes

BACKGROUND: Anti-factor Xa assays and activated partial thromboplastin time (aPTT) are mainly employed to monitor patients treated with heparins. According to the Clinical and Laboratory Standards Institute and the French Working Group on Haemostasis and Thrombosis, anti-factor Xa activity and aPTT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gremillet, Marion, Talon, Laurie, Lebreton, Aurélien, Sinegre, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942401/ https://www.ncbi.nlm.nih.gov/pubmed/36803983 http://dx.doi.org/10.1186/s12959-023-00465-8

Ejemplares similares

Analytical performance of a new immunoturbidimetric D‐dimer assay and comparison with available assays
por: Talon, Laurie, et al.
Publicado: (2022)

CTAD as a universal anticoagulant
por: Yokota, M., et al.
Publicado: (2003)

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019)

Comparison of Commercially Available Blood Collection Tubes Containing Sodium Citrate and Hirudin in Platelet Aggregation Testing
por: Janse Van Rensburg, Walter J., et al.
Publicado: (2017)

Nutrition-Based Approaches in Clinical Trials Targeting Cognitive Function: Highlights of the CTAD 2020
por: Giudici, Kelly Virecoulon
Publicado: (2021)

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016)

Citrate Anticoagulation for CRRT in Children: Comparison with Heparin
por: Fernández, Sara Nicole, et al.
Publicado: (2014)

Characterization of the dynamics and the conformational entropy in the binding between TAZ1 and CTAD-HIF-1α
por: Nyqvist, Ida, et al.
Publicado: (2019)

Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report
por: Gauthier, Serge, et al.
Publicado: (2020)

Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022)

Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition
por: Rashid, Qudsia, et al.
Publicado: (2014)

Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
por: Xu, Lengnan, et al.
Publicado: (2023)

Impact of Epicatechin on the Procoagulant Activities of Microparticles
por: Sinegre, Thomas, et al.
Publicado: (2020)

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
por: Meihandoest, Tamana, et al.
Publicado: (2022)

Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force
por: Aisen, P. S., et al.
Publicado: (2021)

Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force
por: Kaye, Jeffrey, et al.
Publicado: (2021)

Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?
por: Oudemans-van Straaten, Heleen M, et al.
Publicado: (2011)

Monitoring Low Molecular Weight Heparins at Therapeutic Levels: Dose-Responses of, and Correlations and Differences between aPTT, Anti-Factor Xa and Thrombin Generation Assays
por: Thomas, Owain, et al.
Publicado: (2015)

Stability of 21 Antihypertensive Drugs in Serum Collected in Standard (Nongel) Serum Tubes Versus Tubes Containing a Gel Separator
por: Hegstad, Solfrid, et al.
Publicado: (2020)

Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)
por: Shuren, J., et al.
Publicado: (2022)

Stability of citrate and calcium dosing in citrate renal replacement therapy
por: Sadaat, F, et al.
Publicado: (2015)

Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms
por: Whitman-Purves, Emily, et al.
Publicado: (2017)

Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes
por: Hornung, Paul, et al.
Publicado: (2020)

Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
por: Lawlor, Matthew, et al.
Publicado: (2021)

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?
por: Nguyen, Tung Phi, et al.
Publicado: (2021)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
por: Nguyen, Lily, et al.
Publicado: (2023)

Comparative metabolomics studies of blood collected in streck and heparin tubes from lung cancer patients
por: Goldberg, Erin, et al.
Publicado: (2021)

Blood transfusion requirements and filter longevity with regional citrate anticoagulation compared with heparin
por: Burford, E, et al.
Publicado: (2015)

Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children
por: Raymakers-Janssen, Paulien A. M. A., et al.
Publicado: (2017)

Citrate-Stabilized Gold Nanorods
por: Mehtala, Jonathan G., et al.
Publicado: (2014)

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
por: Trunfio, Mattia, et al.
Publicado: (2020)

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
por: Angioni, D., et al.
Publicado: (2022)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Heparin-free regional anticoagulation of haemodialysis filters with calcium-free dialysate: is citrate mandatory?
por: Medrano, Chloé, et al.
Publicado: (2021)

Clinical Trial Comparing the Efficacy and Safety of Regional Citrate Anticoagulation Versus Heparin in CRRT
por: Senthilkumar, S, et al.
Publicado: (2023)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Relationship between peak anti-Xa levels and calculated creatinine clearance in ICU patients receiving low molecular weight heparin
por: McDonald, E, et al.
Publicado: (2003)

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
por: Rhoades, Ruben, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3j7jfadlcricqemc6l31pgc5iq